AIM
NBIX icon

Achmea Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Achmea Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,333
Closed -$1.03M – 361
2025
Q1 		$1.03M Hold
9,333
– – 0.02% 326
2024
Q4 		$1.27M Buy
9,333
+971
+12% +$120K 0.02% 328
2024
Q3 		$963K Buy
8,362
+5,219
+166% +$715K 0.02% 365
2024
Q2 		$433K Buy
3,143
+754
+32% +$103K 0.01% 394
2024
Q1 		$329K Sell
2,389
-4,299
-64% -$587K 0.01% 418
2023
Q4 		$882K Sell
6,688
-2,967
-31% -$342K 0.02% 400
2023
Q3 		$1.09M Sell
9,655
-199
-2% -$21K 0.02% 382
2023
Q2 		$930K Sell
9,854
-213
-2% -$20.8K 0.02% 436
2023
Q1 		$1.02M Buy
10,067
+1,619
+19% +$168K 0.03% 391
2022
Q4 		$945K Buy
8,448
+2,710
+47% +$317K 0.03% 406
2022
Q3 		$609K Buy
5,738
+5,539
+2,783% +$562K 0.02% 458
2022
Q2 		$20K Hold
199
– – ﹤0.01% 597
2022
Q1 		$19K Buy
+199
New +$16.9K ﹤0.01% 620
2021
Q4 		– Sell
-199
Closed -$19K – 436
2021
Q3 		$19K Buy
+199
New +$18.8K ﹤0.01% 606

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Achmea Investment Management's NBIX Position: Q2 2025 in Review

Achmea Investment Management sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 9,333 shares — an estimated $1.03M sold.

Achmea Investment Management first reported a position in NBIX in Q3 2021 and held it in 14 quarters. The position peaked at $1.27M in Q4 2024. 585 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

  • Achmea Investment Management reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
  • Achmea Investment Management sold 9,333 Neurocrine Biosciences shares in Q2 2025, an estimated $1.03M.
  • Achmea Investment Management first reported a position in Neurocrine Biosciences in Q3 2021 and held it in 14 quarters.
  • Achmea Investment Management's Neurocrine Biosciences position peaked at $1.27M in Q4 2024.
  • 585 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on Achmea Investment Management's 13F filing for Q2 2025, filed 6 Aug 2025.